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Background: Factors capable of impacting hospital mortality in patients with septic shock remain uncertain. Our
objective was to identify predictors of hospital mortality among patients who received appropriate antimicrobial
therapy for bacteremic septic shock after accounting for severity of illness, resuscitation status, and processes of care.
Methods: We conducted a secondary subgroup analysis of a prospective severe sepsis cohort study. Patients with
septic shock and positive blood cultures who received appropriate antimicrobial therapy were included. Univariable
analyses were used to identify differences between hospital survivors and non-survivors, and a multivariable logistic
regression model revealed independent determinants of hospital mortality.
Results: From January 2008 to December 2010, 58 of 224 included patients died in the hospital. Multivariable logistic
regression analysis demonstrated 2 independent predictors of hospital mortality. These included continuous renal
replacement therapy utilization within 48 hours of septic shock recognition (adjusted odds ratio [OR], 5.52; 95%
confidence interval [CI], 1.94-16.34) and intra-abdominal infection (adjusted OR, 3.92; 95% CI, 1.47-10.79). Escherichia coli
was independently associated with a lower risk of hospital mortality (adjusted OR, 0.34; 95% CI, 0.11-0.90).
Conclusion: Intra-abdominal infection and continuous renal replacement therapy were associated with increased
hospital mortality in patients with septic shock who received appropriate antimicrobial therapy. Our findings may be
explained by suboptimal intra-abdominal infection management or inadequate antimicrobial concentration in these
patients.
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Severe sepsis and septic shock account for up to 10% of
intensive care unit (ICU) admissions, and the incidence
of this syndrome is anticipated to reach 1.1 million cases
annually in the United States by 2020 [1,2]. Scripted
treatment guidelines from the Surviving Sepsis Cam-
paign [3] and the Institute for Healthcare Improvement
[4] have focused on a bundled approach to care, yet global
compliance remains poor [5]. Within the septic shock
treatment armamentarium, a directed approach that in-
cludes both appropriate and timely antimicrobial therapy
continues to be a cornerstone of treatment, with ample* Correspondence: schramm.garrett@mayo.edu
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reproduction in any medium, provided the orevidence supporting an association between inappropriate
or delayed prescription of antimicrobials and increased
patient mortality [6-9].
Despite advances in recognition and treatment of
septic shock, hospital mortality remains alarmingly high,
ranging from 30% to over 50% in recent publications
[5,10,11]. Documented bacteremia has been proposed
as the fundamental pathophysiological determinant of
sepsis, and although not a requirement for diagnosis,
bacteremia should be established in septic patients when
possible [10,12,13]. Outcomes in bacteremic sepsis have
been influenced by age, sex, severity of illness, albumin,
comorbidities, pathogen, and source. Although prompt
administration of appropriate antimicrobial therapy may
improve hospital survival, predictors of mortality in
bacteremic septic shock remain largely unknown whenl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Leedahl et al. BMC Anesthesiology 2014, 14:21 Page 2 of 8
http://www.biomedcentral.com/1471-2253/14/21appropriate antimicrobials are administered [9]. Thus,
we hypothesized that independent risk factors for hos-
pital mortality exist in bacteremic patients with septic
shock who received appropriate antimicrobial therapy
while accounting for Acute Physiology and Chronic
Health Evaluation (APACHE) III score, preference of
care, and processes of care, including compliance with
non-antimicrobial elements of our sepsis resuscitation
bundle.
Methods
In a secondary subgroup analysis of a prospective obser-
vational trial, we evaluated 1304 patients with septic
shock to identify risk factors for hospital mortality and
further improve the delivery of care at our institution.
Data were from patients admitted to a 24-bed medical
ICU of Mayo Clinic, Rochester, MN, from January 2008
through December 2010. The study was approved by the
Mayo Clinic Institutional Review Board (IRB# 11-004905)
and therefore was performed in accordance with the
ethical standards laid down in the 1964 Declaration of
Helsinki and its later amendments. Informed authorization
was obtained from patients for their involvement in the
original prospective study. The Mayo Clinic IRB waived
the requirement for informed consent for our study, and
all included patients authorized their medical records to
be reviewed for research. Our original prospective study
included patients with suspected infection, age ≥18 years,
and with systolic blood pressure <90 mm Hg, despite
a fluid challenge of 20 ml/kg body weight of crystal-
loid or lactate level >4 mmol/L. Patients who refused sep-
tic shock resuscitation (including placement of a central
catheter), or experienced active bleeding or cardiogenic
pulmonary edema were excluded [14]. Our secondary co-
hort analysis included patients who had microbiologically
confirmed bacteremia upon initial blood cultures, re-
ceived appropriate antimicrobial therapy within 24 hours
and met consensus criteria for septic shock. All patients
included in the study timeframe were admitted in our
medical ICU after implementation of daily auditing and
weekly feedback regarding sepsis resuscitation bundle
compliance [14]. Only the index episode of septic shock
was included for patients with a recurrent episode within
the study timeframe. The study ICU was staffed by a
multidisciplinary team lead by intensivists, with 24/7 in-
house coverage [15].
Data elements
The following information was collected for each patient:
demographics (age, gender, race), ICU admission source,
APACHE III score, hospital length of stay, compliance with
individual sepsis bundle elements, antimicrobials adminis-
tered, renal replacement modalities utilized, do not resusci-
tate (DNR) status in case of cardiac arrest at time of septicshock recognition, initial plasma lactate level, and hospital
mortality. An additional file provides a description of
our sepsis bundle elements in more detail (see Additional
file 1). Severity of illness was assessed using APACHE III
scores, which were calculated using technology at our in-
stitution as described previously [16]. We recorded patho-
gens from all microbiology cultures and antimicrobials
administered within 24 hours of blood culture or septic
shock recognition, whichever occurred first.
Definitions
Septic shock was defined per the American College of
Chest Physicians and Society of Critical Care Medicine
consensus criteria [17], with the definition of bacteremia
being consistent with International Sepsis Forum Con-
sensus Conference recommendations [12]. The time of
septic shock recognition was defined as the time of doc-
umented hypotension despite 20 ml/kg of crystalloid.
For patients transferred from outside hospitals to our
institution with septic shock, the ICU admission time
was considered the time of recognition. Appropriate anti-
microbial therapy was defined as antimicrobial agent(s)
administered within 24 hours of septic shock recognition
to which pathogen(s) that were subsequently isolated
and identified from all available microbiology cultures
(in addition to blood cultures) had documented in vitro
susceptibility, consistent with other investigations [6,7,11].
Preference of care was defined as the presence of “DNR in
case of cardiac arrest” status in the electronic medical rec-
ord at the time of septic shock recognition, and was col-
lected due to previous investigations regarding the impact
of preference of care on post-ICU mortality [18]. During
the study timeframe, a sepsis response team (SRT) was
implemented in our ICU to improve the process of patient
care [14]. Decisions regarding the choice and duration of
antimicrobial agents were at the discretion of treating phy-
sicians and made in collaboration with clinical pharma-
cists. The source of bacteremia was documented in the
electronic medical record and was classified as either
primary (catheter, implantable cardioverter-defibrillator,
pacemaker, arteriovenous fistula, ileal conduit, or endocar-
ditis related) or secondary. If a secondary source of infec-
tion was suspected, the infection source was designated as
skin/soft tissue, respiratory, urinary, intra-abdominal (IA),
and others. When a secondary source of infection was
not documented, the source was classified as unknown.
Staphylococcus epidermidis was not considered pathogenic
as described previously [8]. Candida species from blood
were considered pathogenic, but Candida species isolated
from bronchioalveolar lavage, sputum, tracheal secretion,
and urine without documented candidemia were consid-
ered colonizers. Stress dose steroid administration was de-
fined as receiving ≥ 50 mg of intravenous hydrocortisone
during the first 24 hours after septic shock recognition.
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universally susceptible to oral and intravenous metro-
nidazole or oral vancomycin. Clostridium difficile related
diseases were considered an IA source of bacteremia.
Source control of IA infection during hospital admission
was defined as any abdominal drainage of infected foci
or a surgical procedure to control IA contamination in
an attempt to restore anatomic and physiological integ-
rity, according to Infectious Diseases Society of America
guidelines [19].
Continuous renal replacement therapy (CRRT)
The CRRT modality of choice for adults at our institu-
tion is continuous veno-venous hemofiltration (CVVH),
which removes solutes by convection. All CVVH treat-
ments applied the Prismaflex System and the HF 1400
polyarylethersulfone filter (Gambro, Stockholm, Sweden).
The standard blood flow rate was 200 ml/min, with so-
dium citrate anticoagulation. Prismasate (Gambro, Inc.,
Lakewood, CO) replaced the hemofiltration fluid, cus-
tomarily administered 50% prefilter and 50% postfilter.
No formal criteria existed for CVVH initiation during the
study period. Use of CVVH was per intensivist and at-
tending nephrologist discretion and individualized for
each patient.
Antimicrobial susceptibility
Our microbiology laboratory services performed anti-
microbial susceptibility of isolates using a non-automated
agar dilution method according to breakpoints established
by the Clinical and Laboratory Standards Institute and
in publication between 2008 and 2010 [20-22]. Suscep-
tibility profiles of isolates were based on in vitro ana-
lysis using established breakpoints. The classification of
intermediate-resistance in vitro was considered resistant
for our study.
Statistical analysis
Categorical variables were summarized as frequency (%)
and compared between hospital survivors and non-
survivors using chi squared tests. Continuous variables
were expressed as mean ± standard deviation or median
with interquartile range (IQR) as appropriate. Continu-
ous variables were compared using t-tests for parametric
data or Wilcoxon analysis for nonparametric data. It was
determined that 175 patients would provide 80% power
to detect a two-fold increased risk of hospital mortality
for a given variable, assuming 40% nonsurvivors and an
alpha level of 0.05. Baseline, epidemiologic, and treat-
ment variables were initially assessed by univariable ana-
lyses. Variables associated with and clinically relevant to
the dependent outcome of increased hospital mortality
with a p-value ≤ 0.1 were included in multivariable analysis.
In the event that two related variables were determined tohave a p-value <0.1 (such as gram positive infection and
Staphylococcus aureus infection), the more specific variable
was included in multivariable analysis. To promote a reli-
able multivariable model, the authors decided a priori to
adjust the multivariable model for the following variables:
APACHE III score (severity of illness), DNR in case of
cardiac arrest status (preference of care), enrollment after
implementation of a SRT in the study ICU, timing of ap-
propriate antimicrobial therapy, and compliance with non-
antimicrobial elements of the sepsis resuscitation bundle
(processes of care). Only cumulative mortality rates were
estimated using Kaplan-Meier methodology to describe
mortality at week 1 and 2 after septic shock recognition.
Multivariable logistic regression analysis was performed to
identify independent predictors of hospital mortality.
A p-value of <0.05 was considered statistically significant
in multivariable analysis. Data were analyzed using JMP
software, version 9.0.1 (Cary, NC).
Results
Of the 1304 episodes of septic shock evaluated, 491
patients had at least one positive microbiologic culture
and 224 met inclusion and exclusion criteria (Figure 1).
APACHE III score was the only baseline characteristic
statistically associated with hospital mortality by univari-
able analysis (Table 1). Fifty-eight of 224 patients died in
the hospital, and the cumulative mortality rates within 1
and 2 weeks were 12.1%, 18.75%, respectively. The max-
imum observed length of stay was 164 days, whereby the
cumulative mortality rate was 39.2%. The median length
of stay was 8 days, and the median time to death for
patients who died in the hospital was 6.5 days (IQR 2-
15 days). Epidemiologic and clinical characteristics of the
bacteremic infections are summarized in Table 2.
The impact of each antimicrobial on hospital mortality
was analyzed independently during univariable analyses
(Table 2). Vancomycin, fluoroquinolones, and piperacillin/
tazobactam were the most frequently prescribed antimicro-
bials, administered to 84%, 77%, and 52% of patients, re-
spectively. Patients receiving appropriate antimicrobial
therapy within 1 hour were evenly distributed between
hospital survivors and non-survivors (p = 0.328). The me-
dian time to appropriate antimicrobial therapy for the en-
tire cohort was 0 hours (IQR 0-1.0, minimum 0 hours,
maximum 23.0 hours), but the median time to appropriate
antimicrobial therapy was statistically different between
groups (Table 2). Metronidazole was the only antimicrobial
agent associated with increased hospital mortality upon
univariable analysis (Table 2). Secondary analyses revealed
that patients who received metronidazole had no statisti-
cally significant differences in the following variables when
compared to those not receiving metronidazole: age, base-
line serum lactate, IA source of infection, source control
procedures for IA infection, utilization of CRRT within
Figure 1 Cohort development.
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sors (analysis reports not shown).
Gram positive infections were associated with a higher
risk of hospital mortality by univariable analysis (Table 2).
Escherichia coli was the only pathogen statistically more
common in survivors (Table 3). Patients with septic
shock related to E. coli infection were not statistically
younger, nor were their median APACHE III score or base-
line lactate lower compared to patients with non-E. coli
infections.
Urinary source of infection was associated with in-
creased hospital survival, while IA source of infection
was predictive of increased hospital mortality despite
similar rates of source control procedures for IA source
of infection between groups (Table 2). For patients with
IA source of infection, the median time to source con-
trol was 13.7 hours (IQR 3.9-54.5 hours) and did notTable 1 Baseline characteristics
Survivors Non-survivors
P
n = 166 n = 58
Caucasian (%) 155 (93.4) 53 (91.4) 0.612
Male gender (%) 98 (59.0) 30 (51.7) 0.333
Age, years, median (IQR) 72 (58-81) 72 (63-80) 0.534
APACHE III score, median (IQR) 58 (47-72) 67 (53-80) 0.014
Admission from emergency
department (%)
101 (60.8) 35 (60.3) 0.947
Transfer from outside facility (%) 25 (15.4) 6 (10.3) 0.371
Do not resuscitate in case of cardiac
arrest (%)
36 (21.7) 15 (25.9) 0.514
Lactate, mmol/L, median (IQR) 2.6 (1.7-3.9) 3.02 (2.0-4.7) 0.151
Enrolled after sepsis response team
implementation at study ICU (%)
119 (71.7) 40 (69.0) 0.849
APACHE, Acute Physiology and Chronic Health Evaluation score; SD, standard
deviation; IQR, interquartile range.differ significantly between hospital survivors and non-
survivors (Table 2). During the study period, 55% of
patients had full compliance with non-antimicrobial ele-
ments of the sepsis resuscitation bundle. Compliance
with individual sepsis bundle elements was not statistically
different between hospital survivors and non-survivors
(Table 4).
Four variables with a p-value of <0.1 by univariable
analysis were not included in multivariable analysis (gram
positive infection, gram negative infection, gram positive
aerobe isolate, gram negative isolate) due to a more spe-
cific, related variable in the multivariable model (Staphylo-
coccus aureus and E. coli infection). Utilization of CRRT
within 48 hours and IA source of infection were independ-
ently associated with increased hospital mortality by
multivariable logistic regression analysis, and septic
shock related to E. coli infection was independently asso-
ciated with a lower risk of hospital mortality (Table 5).
An interaction between E. coli infection and urinary
source of infection was not observed. A sensitivity ana-
lysis was also conducted whereby patients transferred
from an outside facility were excluded, yielding similar
results (Additional file 2).
Discussion
Our study offers additional perspective to sepsis mortality
literature, which has customarily reported poor patient
outcomes due to delayed or inappropriate antimicrobial
administration [6-9]. The current body of literature ad-
dressing predictors of septic shock mortality is remarkably
limited to date, especially in the setting of appropriate
antimicrobial therapy, bundled sepsis treatment, and
a dedicated SRT. We highlight CRRT and IA source
of infection as independent risk factors for hospital
mortality after adjusting for severity of illness, prefer-
ence of care, and processes of care including compliance
Table 2 Epidemiologic and clinical characteristics of the







n = 166 n = 58
IHD within 48 hours 9 (5.4) 5 (8.6) 0.386
CRRT within 48 hours 11 (6.6) 15 (25.9) <0.01
Stress dose steroid 61 (36.8) 29 (50.0) 0.076
Gram stain of organisms isolated from all cultures
Fungi or parasite 4 (2.4) 1 (1.7) 0.761
Gram positive 48 (28.9) 26 (44.8) 0.027
Gram negative 80 (48.2) 21 (36.2) 0.114
Polymicrobial 34 (20.5) 10 (17.2) 0.593
Concomitant positive culture (when culture results available)
Respiratory 17 (13.4) 8 (18.6) 0.404
Urine 53 (34.4) 10 (20.4) 0.065
Primary bacteremia 16 (9.6) 9 (15.5) 0.221
Source of infection if secondary bacteremiaa,b
Skin soft tissue 20 (12.1) 6 (10.3) 0.727
Respiratory 30 (18.1) 11 (19.0) 0.880
Urinary 57 (34.3) 9 (15.5) 0.007
Intra-abdominal 20 (12.1) 16 (27.6) 0.006
Unknown 22 (13.3) 5 (8.6) 0.351
Source control procedure if
intra-abdominal sourcec
16 (80.0) 13 (81.3) 0.925
Median time to source control,
hours (IQR)c
13.5 (0.7-65.0) 13.9 (4.9-51.4) 0.568
Vasopressor for at least 1 hour 96 (57.8) 43 (74.1) 0.028
Antimicrobials administeredd,e
Carbapenem (not ertapenem) 48 (28.9) 11 (19.0) 0.139
Cefepime 33 (19.9) 17 (29.3) 0.138
Ceftriaxone 20 (12.1) 10 (17.2) 0.318
Clindamycin 9 (5.4) 4 (6.9) 0.679
Fluoroquinolone 130 (78.3) 43 (74.4) 0.514
Levofloxacin 103 (62.1) 32 (55.2) 0.357
Metronidazole 12 (7.2) 11 (19.0) 0.011
Piperacillin/tazobactam 89 (53.6) 28 (48.3) 0.484
Vancomycin 142 (85.5) 47 (81.0) 0.416
Antifungal agent 4 (2.4) 2 (3.5) 0.673
Appropriate antimicrobial therapy
administered <1 hr
128 (77.1) 41 (70.7) 0.328
Time to appropriate antimicrobial
therapy, hours, median (IQR)
0 (0-0.87) 0.23 (0-1.08) 0.033
IHD, intermittent hemodialysis; CRRT, continuous renal replacement therapy;
IQR, interquartile range. an = 150 survivors, 49 non-survivors; b1 case of each
(not included in analysis): periodontal, ear, kidney stone; cn = 36; dDue to
administration of ≥ 1 antimicrobial per patient, total n is >224; eAntimicrobials
with <5 administrations not included in analysis.






n = 166 n = 58
Gram negative aerobes 99 (59.6) 26 (44.8) 0.051
E coli 51 (30.7) 7 (12.1) 0.005
Klebsiella spp 23 (13.9) 9 (15.5) 0.756
Pseudomonas aeruginosa 8 (4.8) 4 (6.9) 0.545
Other gram negative 22 (13.3) 8 (13.8) 0.917
Gram positive aerobes 66 (39.8) 33 (56.9) 0.024
Staphylococcus aureus 27 (16.3) 16 (27.6) 0.060
Methicillin susceptible 13 (7.8) 8 (13.8) 0.180
Methicillin resistant 14 (8.4) 8 (13.8) 0.238
Streptococcus pneumoniae 12 (7.2) 5 (8.6) 0.730
Enterococcus spp 14 (8.4) 7 (12.1) 0.414
Other gram positive 14 (8.4) 5 (8.6) 0.968
Anaerobes 5 (3.0) 2 (3.5) 0.869
Fungi 4 (2.4) 1 (1.7) 0.761
aDue to ≥ 1 blood isolate per patient, total n is >224.
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Labelle and colleagues recently conducted a retrospective
study of bacteremic septic shock patients receiving appro-
priate initial antibiotic treatment, identifying APACHE II
score and ICU-acquired infection as the most important
determinants of hospital mortality [11]. Alternatively, sep-
tic shock caused by methicillin-susceptible Staphylococcus
aureus (MSSA) infection was independent predictor of sur-
vival, and the investigators subsequently concluded MSSA
infection was a surrogate for lower severity of illness and
younger age. In our cohort, E coli infection was independ-
ently associated with hospital survival, and these patients
did not differ from those with non-E. coli infections in re-
gard to age, APACHE III score, or baseline serum lactate.Table 4 The relationship between mortality and compliance
with non-antimicrobial sepsis bundle elements
Sepsis bundle element Survivors(n = 166)
Non-survivors
(n = 58) P
Lactate measured 163 (98.2) 57 (98.3) 0.967
Blood culture before antibiotics 163 (98.2) 58 (100) 0.303
Adequate fluid 127 (76.5) 45 (77.6) 0.867
Appropriate vasopressor 144 (86.8) 52 (89.7) 0.564
Appropriate red blood cell
transfusion
150 (90.4) 51 (87.9) 0.600
Appropriate inotrope use 103 (62.1) 37 (63.8) 0.813
Full adherence to non-antimicrobial
elements of the sepsis bundle
93 (56.0) 31 (53.5) 0.734
Table 5 Multivariable logistic regression analysis to





therapy within 48 hours
5.52 1.94-16.34 0.001
Intra-abdominal source of infection 3.92 1.47-10.79 0.006
Escherichia coli infection 0.34 0.11-0.90 0.029
APACHE III score, per unit increase 0.99 0.98-1.01 0.323
Vasopressor for at least 1 hour 1.77 0.77-4.21 0.181
Lactate, per 1 mmol/L increase 0.98 0.84-1.13 0.736
Do not resuscitate in case of
cardiac arrest
1.95 0.86-4.40 0.109
Full adherence to non-antimicrobial
elements of the sepsis bundle
0.83 0.38-1.81 0.646








Urinary source of infection 0.72 0.26-1.88 0.506
Staphylococcus aureus infection 2.34 0.95-5.83 0.064
Received metronidazole 2.79 0.99-7.88 0.053
APACHE, Acute Physiology and Chronic Health Evaluation III score; ICU, intensive
care unit.
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by evaluating additional treatment variables in a more re-
cent patient cohort enrolled between 2008 and 2010. How-
ever, patients in our study were not identified by the
presence of International Classification of Disease codes,
but rather by achieving clinical criteria for septic shock. In
addition, our patients received uniform treatment guided
by a sepsis resuscitation bundle during the implementation
of a SRT.
Adjunctive therapies, such as CRRT, are frequently
used to treat critically ill patients with multiple organ
failure. Small retrospective studies have suggested that
early initiation of CRRT may improve clinical outcomes
in septic AKI [23]. However, no consensus exists for the
optimal timing of CRRT in patients with septic shock
and AKI [24], and early CRRT has also been associated
with worse outcomes [25]. Our finding of increased
mortality when CRRT is initiated within 48 hours of sep-
tic shock encourages further investigation into the ap-
propriate timing of CRRT in the setting of severe sepsis
and septic shock.
Utilization of CRRT is indicative of organ dysfunction,
a well-known contributor to sepsis related mortality and
may explain the associated mortality in our study [26].
Additional markers of renal dysfunction were not in-
cluded in our analysis as APACHE III accounts for serumcreatinine, urine output, blood urea nitrogen, and the
presence of acute renal failure. While CRRT may provide
benefit in sepsis [27], CRRT may also clear therapeutic
agents from the body and alter drug pharmacokinetics,
potentially leading to inadequate drug response or treat-
ment failure [28]. The CRRT modality of choice for
adults at our institution is CVVH, which removes solutes
by convection. Although our multivariable model was ad-
justed for APACHE III score, we can not preclude the
possibility that CRRT was a surrogate for severity of ill-
ness or potentially inadequate antimicrobial tissue con-
centrations. Of note, our institution has a standardized
antimicrobial dosing algorithm for patients on CRRT,
which is provided in an additional file (see Additional
file 3).
Intra-abdominal infections are the second most com-
mon cause of septic death in the ICU [29]. Our findings
are similar to those of Labelle and colleagues, who found
IA source of gram-positive bacteremia to be predictive
of hospital mortality in septic shock patients [11]. Add-
itionally, our analysis demonstrated that IA source of
septic shock was predictive of mortality regardless of
pathogen(s) isolated, time to procedural source control, or
whether procedural source control was performed. Our
findings highlight the importance of early identification
and assessment and management of patients presenting
with a suspected IA source of septic shock.
Strengths of our study include that it is the first to in-
vestigate additional modifiable predictors of septic shock
mortality (eg. antimicrobials, renal replacement modal-
ities, sepsis bundle elements) in the setting of appropri-
ate antimicrobial therapy. In addition, we used the time
of documented hypotension, rather than vasopressor ini-
tiation, to identify the time of septic shock recognition.
We also excluded patients without documented bacteremia
in order to derive a septic shock cohort wherein the causa-
tive organism was best defined. Several limitations of our
study must also be noted. Our definition of appropriate
antimicrobial therapy deviates from the current recom-
mendations from the Surviving Sepsis Campaign and the
Institute for Healthcare Improvement. Our criterion was
established to aid in evaluation of possible mortality pre-
dictors in the broader, clinical picture of resuscitation and
management of severe sepsis and septic shock, similar to
the methodology of two recent sepsis-related mortality
investigations [9,11]. Since our study was conducted at a
single ICU with bacteremic patients who were predomin-
antly Caucasian, the findings may not be generalizable to
patients with different baseline characteristics in varying
practice environments or those without positive blood
cultures. Similar to other studies of this nature, we were
limited to recording septic shock recognition as the time
of ICU admission for patients transferred from outside
hospitals. Individual antimicrobials are frequently part of
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septic shock, therefore, statistical analysis of antimicro-
bials independently does not emulate typical prescribing
practices. It is important to recognize that our findings
mainly address the association of various factors with
hospital mortality after septic shock and not necessarily
sepsis-related mortality. Athough all patients receiving
CRRT had a primary renal indication (e.g. oliguria or
anuria, hyperkalemia, fluid overload unresponsive to
diuresis), we cannot exclude the possibility that un-
detected or undocumented differences in the criteria to
start CRRT in our study may have influenced the re-
sults. The relatively large number of data elements ana-
lyzed at the univariable level, like other studies of this
nature, may yield a lack of power to detect associations
of interest between hospital mortality and single vari-
ables. We must note that the statistically significant vari-
ables identified in the multiple logistic regression model
demonstrate unique information about hospital mor-
tality within each variable. Moreover, our analysis re-
vealed an association with hospital mortality beyond
that which may be explained by related variables (CRRT
and APACHE III score). Despite the establishment of ap-
propriate antimicrobial therapy by in vitro susceptibility
to antimicrobials administered, we were not able to ad-
dress the issue of antibiotic adequacy (eg. dosing, thera-
peutic drug levels, drug penetration). Our definition of
appropriate antimicrobial therapy required documented
susceptibility of all subsequently isolated microorganisms
to antimicrobials administered, regardless of sensitivity
profile, and limits the impact of multidrug resistance on
our findings.
Conclusions
In conclusion, the use of CRRT within 48 hours of septic
shock recognition and IA source of infection were inde-
pendent predictors of hospital mortality after adjustment
for severity of illness, preference of care, and processes
of care including compliance with non-antimicrobial ele-
ments of our sepsis resuscitation bundle. Our findings
pertaining to IA infection and CRRT are hypothesis gen-
erating and may be explained by suboptimal IA infection
management or inadequate antimicrobial concentration
in these patients.
Key messages
 Mortality after septic shock remains high despite
advances in recognition and treatment.
 When appropriate antimicrobial therapy is
administered, CRRT within 48 hours and intra-
abdominal source of infection were associated with
increased hospital mortality after accounting for
preference and processes of care. Clinical studies and quality improvement
interventions should focus on the role of intra-
abdominal infection management and the utility
and timing of CRRT in these patients.
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Detailed explanation of the sepsis resuscitation bundle at our institution.
Additional file 2: Independent predictors of hospital mortality by
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whereby patients transferred from an outside facility were excluded,
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our institution.
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